



**XTL Biopharmaceuticals to Present at the Acumen BioFin
Rodman & Renshaw 4th Annual Global Health Care Conference**

VALLEY COTTAGE, NEW YORK, May 9, 2007 – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ram Waisbourd, the Company's Vice President of Business Development, is scheduled to present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Health Care Conference (www.rodmanandrenshaw.com/eu07conference). Mr. Waisbourd will present an overview of the Company including an overview of Bicifadine, the Company's recently in-licensed late-stage clinical compound for the treatment of neuropathic pain. Mr. Waisbourd's presentation will take place on Tuesday, May 15, 2007, at 8:40am local time in Monte Carlo (2:40am Eastern Daylight Time and 9:40am Israel Daylight Time), at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

A live audio webcast of Mr. Waisbourd's presentation will be available at: <http://www.wsw.com/webcast/rrshq11/xtlb>. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase I clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus. XTL's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225